Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Company Overview - Generate Biomedicines, backed by Flagship, experienced a 6.25% decline in its share price during its Nasdaq debut, resulting in a valuation of $1.91 billion [1]. Market Context - The decline in Generate Biomedicines' shares is attributed to ongoing market volatility, which has made investors cautious regarding new listings [1].